Comparison of three galenic forms of lamivudine in young West African children living with Human Immunodeficiency Virus.

Claire PressiatEvelyne DainguyJean-Marc TréluyerCaroline YonabaSaik UrienFrançois EbouaFrantz FoissacDésiré Lucien DahourouNaïm BouazzaKaren MalatesteSophie DesmondeAlain PruvostValériane LeroyDéborah HirtThe Monod Anrs Study Group

Published in: Antiviral therapy (2021)

This trial provided an opportunity to compare three galenic forms (liquid formulation, tablet form and dispersible scored tablet) of lamivudine in the target population of young HIV-1-infected children. Galenic form had no significant effect on lamivudine pharmacokinetics.

Keyphrases

human immunodeficiency virus
hiv infected
antiretroviral therapy
hiv infected patients
hepatitis c virus
young adults
hiv positive
hiv aids
middle aged
clinical trial
study protocol
phase iii
randomized controlled trial
phase ii